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ABSTRACT
Drug-target interaction (DTI) prediction is a fundamental step in drug discovery
and genomic research, and contributes to medical treatment. Various computational
methods have been developed to find potential DTIs. Machine learning (ML) has
been currently used for new DTIs identification from existing DTI networks. There
are mainly two ML-based approaches for DTI network prediction: similarity-based
methods and feature-based methods. In this thesis, we propose a feature-based ap-
proach, and firstly use short-linear motifs (SLiMs) as descriptors of protein. Addi-
tionally, chemical substructure fingerprints are used as features of drug. Moreover,
another challenge in this field is the lack of negative data for the training set because
most data which can be found in public databases is interaction samples. Many re-
searchers regard unknown drug-target pairs as non-interaction, which is incorrect,
and may cause serious consequences. To solve this problem, we introduce a strategy
to select reliable negative samples according to the features of positive data. We use
the same benchmark datasets as previous research in order to compare with them.
After trying three classifiers k nearest neighbours (k-NN), Random Forest (RF) and
Support Vector Machine (SVM), we find that the results of k-NN are satisfied but
not as excellent as RF and SVM. Compared with existing approaches using the same
datasets to solve the same problem, our method performs the best under most cir-
cumstance.
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CHAPTER 1
Introduction
Drug research is necessary for treatment of disease. At the molecular level, proteins
are the main targets for drugs. In this case, identification of drug-target interaction
networks is a fundamental step of genomic drug discovery, drug design and phar-
macology, which is also the problem needed to be addressed in this thesis. Because
biochemical experiments in wet lab (aka in vitro methods) spend too much time,
expense and human resources, computational methods (aka in silico methods) have
been developed to predict drug-target interaction on a large scale nowadays.
1.1 Drug-target Interaction Network
Drug can be defined as a compound (molecular entity) that interacts with one or
more molecular targets and effects a change in biological state [18]. Target proteins
refer to bio-molecules (functional modules) of living organisms [3] formed by amino
acid sequences. There are mainly four types of target proteins commonly known in
humans, which are Nuclear Receptors, G-protein Coupled Receptors (GPCRs), Ion
Channels, and Enzymes. Functions of target proteins can be affected by interacting
with compounds [24], which means that drug compounds can enhance or inhibit
functions carried out by target proteins. Such a pair of drug and its target protein is
regarded as a drug-target interaction, where each drug or protein can be represented
by a node, while an interaction can be shown as a link. In this case, a large number
of drug-target pairs constitute drug-target interaction networks. The data about
drug-target interaction can be obtained from KEGG BRITE [20], DrugBank [38],
1
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Fig. 1: A drug-target interaction network graph [9]
BRENDA [30], SuperTarget and Matador [16], ChEMBL [35] and GLIDA [25].
Fig. 1 shows an example of drug-target interaction network for four benchmark
datasets: Enzymes (red), Ion Channels (orange), GPCRs (blue), and Nuclear Re-
ceptors (black). Circles represent for drugs, while rectangles are targets. An edge
between a pair of drug-target means a known interaction. Since the number of known
interactions is quite small, our purpose is to discover new drug-target interactions
based on known information to enlarge the network.
1.2 Research Motivation
The amount of known drug-target interactions is limited, so more interactions need
to be detected in order to support drug research. Many researchers focus on in silico
drug-target interaction prediction because of labor-intensive, time-consuming and
costly experimental process. As the assistance of in vitro experiments, computational
2
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methods provide much useful information to narrow down experimental subjects.
There are mainly two aspects in terms of in silico methods: docking simulation and
machine learning. The main idea of docking simulation is to simulate the molecular
recognition process between drug and its targets on the computer, which requires
3-dimensional structures for both of them. Characteristics of binding behaviours
can be observed clearly during simulation. However, there is a severe limitation
that 3-dimensional structures of most membrane proteins cannot be found in public
databases. Thus, facing to an enormous amount of target proteins, machine learning
is an appropriate choice which is used in this thesis. Moreover, approaches based
on machine learning can also be categorized into two aspects: similarity-based and
feature-based. More details about previous research in this field will be explained in
Chapter 2 Review of the Literature.
Feature-based is the method we use in this thesis. In previous research, n-gram
has been used as the feature of protein, which is a simple chain consisting of n
amino acids with no meaning. However, short-linear motifs (SLiMs) are different
from n-gram although they are both composed of amino acids. SLiMs are involved
in recognition and targeting activities, which may contain the information relevant
to binding with compounds. The concept of SLiMs has been used to predict protein-
protein interaction, and gained a satisfied result, but no one has tried it in the field of
drug-target interaction prediction.Thus, we firstly use SLiMs as features of proteins
in this thesis.
Another problem is that only interaction data which normally called positive data
can be obtained in public databases. Although some drugs and proteins are not
shown as interacted, it does not mean they are non-interacted. It is possible that the
interaction relationship has not been discovered, or their interactions are relatively
weak, so they are not shown as positive. Many researchers regard all the unknown
data as negative samples (non-interactive data), which is incorrect, and may cause
serious consequence. In this case, negative samples selection is a crucial problem.
Based on the strategy proposed by [33], we propose a new approach considering the
degree of drugs and proteins.
3
1. INTRODUCTION
1.3 Problem Restatement
In conclusion, the number of known DTIs data is quite a few, so we need to find
target proteins for more drug compounds to enlarge DTI network. The problem can
be defined as follows. Given a new pair of drug and protein, we aim to predict whether
they are interacted or not, so that potential DTIs can be found. This research is very
valuable which contributes to medical treatment, such as new drug discovery or drug
side effects study. To solve this problem, the main idea of ML-based method is to
build models based on known DTIs data by different classification algorithms, and use
them to do prediction. Among ML-based methods, we use feature-based approach,
and firstly use SLiMs as the feature of protein.
4
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Review of the Literature
This chapter reviews the previous research and publication on prediction of drug-
target interaction networks using machine learning (ML) method, which can be
mainly categorized into two aspects: similarity-based [12][14] and feature-based [6][24][13].
They will be introduced in details below. Beside of these, there are some graph-based
approaches, such as network diffusion [9], and random walk [8].
2.1 Similarity-based Method
The main idea of similarity-based methods is based on drug and protein respective
similarity matrixes to make a prediction. The element of i-th row and j-th column in
drug similarity matrix is the similarity of drug i and drug j. In the same way, protein
similarity matrix stores the similarity score among proteins. [12] introduces several
models of similarity-based method, such as nearest neighbour (NN) [5], bipartite local
models (BLM) [5][4][23], pairwise kernel method (PKM) [19], and etc.
Concerning NN method, they create a binary vector for each drug to present
whether a target protein interacts with this drug or not, which is called drug in-
teraction profile. Similarly, target protein interaction profile can also be generated.
Given a new drug, its most similar known drug can be obtained according to drug
similarity matrix, and called as nearest neighbours (NN). The interaction profile of
a new drug can be computed by multiplying each value of its NN interaction profile
by their similarity score. Interaction profile of a new target is generated in the same
way. The average of these two results is the final score. NN is a very efficient model
5
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Table 1: The values of AUC among NN, BLM, PKM for different datasets
Models Enzyme Ion Channel GPCR Nuclear Receptor
NN 0.898 0.889 0.852 0.820
BLM 0.928 0.918 0.884 0.694
PKM 0.966 0.967 0.937 0.856
spending less time.
BLM extends the method of local models. Given an unknown pair of drug and
target. In order to predict whether they are interacted, they first focus on this drug,
and give every known target a label as +1 or −1 based on interaction data, which aims
to divide them into two classes. Then train an SVM classifier according to protein
similarity matrix which is regarded as attribute vectors of targets to predict the label
of this unknown protein. The unknown drug can also be predicted in a similar way.
This method costs a large computation because it needs to train two classifiers for
every unknown pair of drug and protein prediction.
PKM is an SVM-based method. Based on the similarities between two proteins
and two drugs, they obtain a similarity score of these two drug-target pairs by sim-
ilarities multiplication. In this case, a similarity matrix of drug-target pairs can be
created, and named as kernel matrix. They regard interacted and non-interacted data
as two classes, and kernel matrix as the input to train an SVM classifier. Compare
with the other two methods mentioned above, the result of PKM performs the best.
Table 1 shows AUC values of these three models for different datasets.
2.2 Feature-based Method
The main idea of feature-based method is to find different descriptors for both proteins
and drugs, then generate feature matrix which is represented by feature vectors for all
interaction and non-interaction data to do prediction. Different papers use different
drug-target representations.
6
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2.2.1 Structural and Physicochemical Properties
[6] proposes a feature-based method to predict drug-target interaction, and uses
MACCS fingerprints as features of drug, while use protein sequential representation
as features of protein.
New Idea
This paper extends structure-activity relationship (SAR) methodology, and uses drug
topological structures and protein sequential representation.
Datasets
This paper uses the benchmark datasets which are proposed by [39] in 2008. These
datasets are used in much research, and they are divided by four types of target pro-
teins, which are nuclear receptor, G-protein coupled receptors (GPCR), ion channel,
and enzyme. It shows interactions between drug and its target protein. The number
of proteins in these four datasets is 26, 95, 204, 664 respectively, and the number of
drugs is 54, 223, 210 and 445 respectively. Moreover, there are 90, 635, 1476 and
2916 interactions between a pair of drug-target.
Datasets only show interaction pairs which are also known as positive data, so
authors need to select negative data (non-interactive samples) in the first step. They
regard all the unknown pairs as negative data, which means that all the possible
drug-target combinations except positive samples are negative ones. In this case, the
data is unbalanced, and may cause bias. To solve this problem, Negative samples are
randomly selected as one to two times of positive ones. Authors generate ten different
negative samples in the same way.
Methodology
MACCS substructure fingerprints are used as drug descriptors, which use a dictio-
nary of MDL keys consisting of 166 features. Each feature is a functional molecular
fragment. If a fragment can be found in this drug, then set the value of this position
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as 1. If the feature is not included in this drug, then set it as 0. In this case, a
166-dimensional vector can be generated for each drug.
Fig. 2: Amino acids attributes and division
To present proteins, the authors use four types of descriptors, which are amino
acids, composition (C), transition (T) and distribution (D). Amino acid chains need
to be obtained first for each protein. Regarding amino-acid property consisting of 20
kinds of amino acids, it shows the number of each kind of amino acid in a protein
sequence. Moreover, according to seven different attributions such as hydrophobicity,
polarizability, polarity, and etc, amino acids can be divided into 3 groups for each
attribute, which are shown as Fig. 2. The value of C, T and D can be calculated
based on Fig. 2. First, they assign every amino acid in protein sequence an index from
1. Then according to hydrophobicity division, they give each amino acid a number
of ‘1’, ‘2’, or ‘3’, and compute the number of amino acids marked as ‘1’, ‘2’, or ‘3’
separately denoted by n1, n2 and n3 respectively. In term of descriptor C, there are
3 features including a composition of group 1, 2 and 3. They can be calculated as
np × 100/(n1 + n2 + n3), where p means the pth group. There are still 3 features of
descriptor T, which are the transition from group ‘1’ to group ‘2’ (or ‘2’ to ‘1’), from
group ‘1’ to group ‘3’ (or ‘3’ to ‘1’), and from group ‘2’ to group ‘3’ (or ‘3’ to ‘2’). After
score the number of each transition, they denote them as ni, nii and niii. In this case,
the value of each feature in T can be computed as (nj/(ni + nii + niii))× 100 where
j means one transition. Concerning the last type D, assume that there are Na amino
acids for group 1, they can find out the index of the first amino acid in this group,
8
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Table 2: Performances comparison between 5-fold and independent validation
Datasets
5-fold cross validation Independent validation set
sensitivity specificity accuracy MCC sensitivity specificity accuracy MCC
Enzyme 90.10 90.64 90.31 79.77 88.23 88.39 88.28 78.27
Ion Channel 89.38 88.20 88.91 77.41 88.27 87.34 87.64 76.32
GPCR 82.54 85.49 84.68 67.10 80.59 84.74 82.97 65.34
Nuclear Receptor 82.35 84.72 83.74 64.55 81.82 81.48 81.63 63.09
and also the first 25%, 50%, 75% and 100% amino acids in group 1, then mark their
indexes in protein sequence as na1 , na2 , na3 , na4 and na5 . There are 5 features for each
group in D, and can be computed as nai/N × 100, where i = 1, 2, 3, 4, 5 respectively,
and N is the length of protein sequence. Other two groups can do the same operation,
so15 features can be obtained totally in terms of D. Repeat the operation above for
all seven functional structures. With the addition of 20 amino acid descriptors, there
are 167 features totally for protein.
After obtaining the features of drug and protein, they combine them together
according to the interaction and non-interaction data. Then they use Support vector
machine (SVM) classifier with 5-fold cross validation and independent validation to
do the prediction, and use grid search to determine the best parameters of SVM.
Results and Discussion
Table 2 shows the results for four datasets, which contains the values of sensitivity,
specificity, accuracy and Matthews correlation coefficient (MCC). The authors draw
a receiver operating curve (ROC) using the value of sensitivity (true positives) and
specificity (false positives) for each dataset. The area under ROC is called AUC,
which is an important measure to validate the performance. The AUC values of
Enzyme, Ion channel, GPCR, and Nuclear receptor are 94.86%, 94.28%, 89.02% and
88.22% respectively.
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2.2.2 PSSM Based Evolutionary Information
[24] proposes a feature-based method, and extract evolutionary from position specific
scoring matrix (PSSM).
New Idea
This paper firstly uses bi-gram as features of protein, and proposes Bigram-PSSM
model to predict drug-target interaction. Besides, authors also use BRS-nonint [43]
algorithm to do negative samples selection. This algorithm is used to select negative
samples in protein-protein interaction area, and this paper firstly uses it in drug-target
interaction.
Datasets
This paper uses the same dataset as [6], and also regards all unknown combinations
as negative data. Authors use two ways selecting negative samples to avoid bias,
random and balanced. Random method is to select data from unknown samples
randomly until reach the similar size as positive samples, while balanced method is
evolved from BRS-nonint algorithm which considers balanced degree distribution of
drugs and proteins in both positive and negative datasets.
Methodology
Authors use 881 molecular substructure fingerprints defined by PubChem database
as descriptors of drugs. After SMILES format of each drug obtained, they use rcdk
package in R to find the fingerprints in this drug, and generate an 881-dimensional
binary vector corresponding to 881 fingerprints. If the corresponding substructure
can be found in drug molecule, then set it as 1. Otherwise, set it as 0.
For representing target proteins, authors propose a method called Bigram-PSSM,
which regards the probabilities of two amino acids extracted from position specific
scoring matrix (PSSM) as features of proteins. Every protein sequence has a PSSM
where each column represents an amino acid. There are 20 kinds of amino acids
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totally, so there are 20 columns in PSSM. Each row means one position in this protein
sequence, so the number of rows in PSSM is the same as the length of the protein
sequence. The value in ith row and jth column is the probability of jth amino acid
occurring in the ith position. If there are N amino acids in a protein sequence, the
value of bi-gram (a pattern of two amino acids) for this protein can be calculated
followed by Equation (1).
Bm,n =
N−1∑
i=1
Pm,i × Pn,i+1(1 6 m 6 20, 1 6 n 6 20) (1)
where Pi,j means the value of i
th column and jth row in PSSM. There are 400
kinds of bi-gram combination, so each protein can be described as a 400-dimensional
vector shown as below:
B = (B1,1, B1,2, ..., B1,20, B2,1, B2,2, ..., B2,10, ..., B20,1, ..., B20,10) (2)
where Bi,j denotes the value of regarding the i
th and jth amino acids as a pattern.
According to the interaction and non-interaction data generated using random and
balanced methods, the authors create a 1281-dimensional vector for each record, which
is combined 881-dimensional drug vector and 400-dimensional protein vector together.
Then they use Support Vector Machine (SVM) classifier to do the classification.
Results and Discussion
Fig. 3 shows ROC curves of Bigram-PSSM model using random and balanced meth-
ods for each dataset, while Table 3 summarizes the statistics measures of Bigram
model. It is obviously that the performance of random sampling is better than bal-
anced one, and also indicates that negative samples selection affects the performance
of model. The authors state that the results are satisfied, and better than other
existing research in terms of AUC.
11
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Fig. 3: ROC curves of Bigram-PSSM model using random and balanced datasets for
benchmark datasets
2.2.3 Class Imbalance-aware Ensemble Learning
[13] is also an feature-based method. Besides of data representation chosen, authors
find that classes imbalance may degrade prediction performance. Thus, this paper
improve the performance by balancing classes.
New Idea
Class imbalance in a challenge in drug-target interaction prediction, and this problem
is divided into two aspects: between class and within-class imbalance. Between-class
12
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Table 3: Performances comparison between random and balanced sampling
Datasets Sampling AUC Sensitivity Specificity Precision
Enzyme
Random 94.8 60.9 99.4 48.9
Balanced 92.8 57.6 99.6 59.1
Ion Channel
Random 88.9 49.5 98.2 49
Balanced 85.5 47.3 98.3 49.8
GPCR
Random 87.2 30.9 98.6 42.8
Balanced 78 3.8 99.9 47.2
Nuclear Receptor
Random 86.9 33.3 98.4 61.4
Balanced 80.3 2.22 99.7 6.67
imbalance means that the number of positive samples is much less than negative
ones, while within-class imbalance means that the numbers of different types of drug-
target interaction are imbalanced. Some previous research ignores this problem. The
authors state that performance will be better after solving this problem.
Data
Data used in this research is collected from DrugBank public database. It consists of
5877 drugs, 3348 target proteins, and 12674 interaction. Similar as the benchmark
dataset used by [6] [24], there is no non-interactive pair in this dataset. They regard all
other pairs which not occur in the positive dataset as negative samples. Additionally,
this dataset mixes all the types together, rather than divided by different types of
proteins like the gold standard dataset.
Data Representation
In terms of drug descriptor, they use Rcpi package to generate the 193-dimensional
vector for each drug. To present target proteins, they regard amino acids, dipeptide,
autocorrelation, quasi-sequence-order, amphiphilic pseudo-amino acid, and informa-
13
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tion of composition, transition, and distribution as features of proteins. Authors try
to combine all the protein properties extracted from [17][42][36] together to generate
a list of 1290 attributes. Then normalize the value of these features.
Methodology
Authors propose a new classification method. Similar as Random Forest, they train
T decision trees as predictors, and average all the scores generated by these decision
trees to get the final score. positive dataset is denoted by P , while negative set is N .
In this case, Pi means a subset of positive instances, and Ni is a subset of negative
instances. To build one decision tree, they randomly select a feature subset names as
Fi, and use it to extract some positive samples Pi. To avoid bias caused by within-
class imbalance, the authors oversample Pi. They use k-means++ method clustering
Pi data into K clusters, and each cluster represents a type of interaction. If there
are 4 types, K will equal to 4. The sizes of these K clusters may be different, and
the largest size is named as maxClusterSize. Then reselect the all these K clusters
from P , until the size is the same as maxClusterSize for each cluster. Pi is replaced
by this new set of positive instances. Next, in order to avoid bias caused by between-
class imbalance, they randomly extract the same number as Pi from negative set N ,
so that |Pi| = |Ni|. They also modify negative samples in Ni by Fi which is the subset
of features. After that, the samples selected in Ni is removed from the original set,
which means each negative sample can only be used once. According to the same
step, they build T decision trees.
Results and Discussion
Compare the value of AUC with Decision Tree (0.760), SVM (0.804), Random Forest
(0.855), k-NN (0.814), this proposed method (0.900) performs the best. The AUC
values of other classifiers are 0.760, RF is the second best one because RF can also
deal with imbalanced classes. Thus, it is verified that predicted performance can be
improved by deal with unbalanced data effectively. Authors also use this method
predict some new drug and new protein interaction. Authors state that this method
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is reliable to do drug-target interaction prediction.
2.3 Summary
Most of the results shown in this three literature are satisfied except [24]. As we
can see in Table 3, the results are not satisfied, where the values of sensitivity and
precision are extremely low. It indicates that TP rate are very low, and it is a terrible
performance, not as satisfied as the authors claimed.
[24] and [13] both state that imbalanced classes have had an influence on final
results, which should be considered in this thesis. Besides, all this three literature
regards all the possible combinations which are not shown as interaction as negative
data for no reason, which is incorrect, and may cause serious consequence. Such data
can only be called as unknown samples because we cannot verify whether they are
interacted or not. Reliable negative data selection is study-worthy.
After reviewing the literature, it can be found that what we need to do is not only
seeking better and more meaningful descriptors to represent drug and protein, but
also considering fully trying to decrease the bad influence from everywhere, such as
imbalanced classes, unreliable negative data, and etc.
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CHAPTER 3
Material and Methodology
In this chapter, we propose a new feature-based method to predict drug-target inter-
action. To put it simply, the main idea of feature-based approach is to find descriptors
of protein and drug respectively, and give them values for both positive and nega-
tive samples as their features to do classification. The datasets and method will be
introduced in detail in this chapter.
Fig. 4 is a flowchart showing every step of the model we proposed. After datasets
obtained, the first step is to determine the representations of protein and drug. In
this thesis, we firstly use short-linear motifs (SLiMs) as features of protein, chemical
substructure fingerprints as features of drug. Then give each feature a value for every
record. Specifically, SLiMs can be scored according to position-specific probability
matrix (PSPM) in two different approaches, while chemical substructure fingerprints
can be converted into a binary vector for each drug. Negative samples selection is also
considered after that. As a result, a drug-target features matrix can be generated as
an input data to do classification.
3.1 Gold Standard Dataset
To be comparable with previous research, we use the same gold standard dataset
which was released by [39] in 2008. The data in this benchmark dataset is taken from
KEGG BRITE, DrugBank, BRENDA and SuperTarget databases, and classified into
four sets according to different types of proteins, which are Nuclear Receptor, GPCR,
Ion Channel, and Enzyme.
16
3. MATERIAL AND METHODOLOGY
Fig. 4: Flowchart of proposed model
Fig. 5 shows the format of the dataset. The first column represents protein codes
which can be used as entries to obtain amino-acid sequences from KEGG database,
while the second column indicates drug codes which can be used to gain molecu-
lar formulas of compounds also from KEGG, and each row means that this pair of
drug-target is interacted. The numbers of proteins in Nuclear Receptor, GPCR, Ion
Channel, and Enzyme datasets are 26, 95, 204 and 664 respectively, while the num-
bers of drugs are 54, 223, 210 and 445 respectively. Moreover, there are 90, 635, 1476
and 2926 known interactions in each dataset separately.
Fig. 5: The format of benchmark dataset
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As we can see, gold standard dataset only shows positive samples. However, in
order to train a model for classification, negative samples are also needed in parallel
with positive ones as two classes in a training set. In this case, reliable negative
samples selection is a necessary step. It is worth noting that we cannot regard all
the unknown samples as negative ones because some of them may have potential
interactive relationships which have not been detected yet, while some may have weak
interactions which do not mean entirely non-interacted although the relationship is
not strong enough. Our purpose is to exclude distractors, and select true negative
samples from unknown data. Then combine positive and negative ones together as a
training set.
3.2 Protein Feature Representation
3.2.1 Short-linear Motif
Concept Introduction
In genetics, a motif is a nucleotide or amino-acid sequence pattern that is widespread
and may have a biological significance [37]. In terms of protein, a motif should be a
meaningful sequence of amino acid pattern extracted from a set of protein sequences.
Short-linear sequence motifs (SLiMs) or minimotifs in protein sequences are short
patterns of 3 to 10 amino acids that have been found to be interesting [1]. SLiMs are
involved in recognition and targeting activities, which may contain the information
relevant to binding with compounds. Thus, we use SLiMs as features of protein.
Fig. 6 shows an expression of Ion Channel No. 86 SLiM. Each letter represents for
an amino acid, and the length of this SLiM is 10, which means there are 10 positions
available for amino acids to place in this pattern. Another type of expression is
[V IA][AS]R[FL][ST ]PY EW [Y H]. [V IA] means amino acid V , I and A are all
possible in the first place, but the probability may be different. The height of letters
shown in Fig. 6 correspond to the probability of amino acids. In other words, the
higher a letter is, the more probability this amino acid occurs. Each possible pattern
18
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Fig. 6: A short-linear motif expression Fig. 7: Flowchart of using MEME to extract
SLiMs
is called a site of this SLiM. For example, V ARFSPY EWY and IARFSPY EWY
are two sites, but they belong to the same SLiM.
Multiple EM for Motif Elucidation (MEME)
Many tools can be used to extract SLiMs, such as Minimotif Miner(MnM) [29], SLiM-
Search [11], SLiMFinder [10] and Multiple EM for Motif Elucidation (MEME) [2]. In
this thesis, we use MEME as the tool to generate SLiMs. MEME use unsupervised
and Expectation Maximization (EM) algorithm to optimize statistical parameters in
order to get motifs from a set of protein, DNA or RNA sequences. It can be installed
locally on Linux, OS X and Cygwin systems, and also provides web server online.
Fig. 7 shows that how to use MEME to extract SLiMs. First, amino acid sequences
need to be obtained from public databases according to protein identifiers shown in
the first column in benchmark dataset. Then, generate a FASTA file which can be
read by MEME, and the format is shown as Fig. 8. This is a text-based format
including protein names followed by their peptide sequences. Each letter represents
an amino acid. Besides, DNA or RNA names with their nucleotide sequences are also
acceptable, but we only consider protein sequences in this thesis. “>” is a symbol
followed by a protein identifier indicating that previous protein sequence is over, and
this is a new one. Its peptide sequence is placed on a new line. After FASTA file
generated, it is regarded as an input file to extract SLiMs according to the command
shell below.
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Fig. 8: FASTA format
meme i n p u t f i l e . f a s t a −oc o u t p u t f i l e −mod anr −nmot i f s 50 −minw 3 −maxw 10
Regarding this command, “inputfile.fasta” is the FASTA file generated as input,
while “outputfile” is the folder name to store results, and it can be set as any name we
want. “-minw” is the minimum size of motifs, while “-maxw” represents the maximum
size. As introduced previously, SLiMs mean the motifs whose size are between 3 to
10, so we set “-minw” as 3, while “-maxw” as 10. “-nmotif” in this command means
the number of motifs needs to be extracted, and it is set as 50 in this instance. Table
4 shows this value for each dataset, where N() means “the number of”. The original
intention of SLiMs amount setting is the same number as proteins. However, 26
SLiMs for Nuclear Receptor dataset is too small to get a satisfying performance, so
it is enlarged to 100. Also, in terms of Enzyme dataset, it spends approximately 340
hours to generate 50 SLiMs. To let the research proceed smoothly, 50 SLiMs is set
tentatively in this thesis.
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Table 4: The number of motifs extracted for each dataset
Datasets N (target proteins) N (SLiMs)
Enzyme 662 50
Ion Channels 204 204
GPCR 95 95
Nuclear Receptors 26 100
Position-specific Probability Matrix
From MEME output file, we can obtain position-specific probability matrix (PSPM)
for every SLiM. Table 5 is the PSPM corresponding to the same SLiMs as Fig. 6.
Each column represents for one amino acid. In this case, there are 20 columns in
PSPM because proteins consist of 20 kinds of amino acids totally. Moreover, each
row represents a position in this SLiM. As we know, the length of No.86 SLiM is 10,
so this PSPM includes 10 rows. The value in this matrix means the probability of
corresponding amino acid occurring in particular position. As we can see from the
first row, amino acid A, I and V are all possible occurring in the first position of
this pattern, and probabilities are 0.1˙, 0.3˙ and 0.5˙ respectively, which tallies with the
information extracted from Fig. 6.
Based on PSPM, we can assign every motif in each protein a sore using two
approaches: I-score proposed by [28], and sliding window method [22], so that a
protein feature matrix can be built as the features of proteins. These two scoring
methods aim to solve protein-protein interaction problem, so after the considering
concrete problem in this thesis, I-score and sliding window approaches are restated.
3.2.2 I-Score Approach
In I-score approach, we regard the SLiMs extracted by MEME as the features of
protein.
21
3. MATERIAL AND METHODOLOGY
Table 5: Position-specific Probability Matrix of Ion Channel No. 86 SLiM
A C D E F G H I K L M N P Q R S T V W Y
0.1˙ 0 0 0 0 0 0 0.3˙ 0 0 0 0 0 0 0 0 0 0.5˙ 0 0
0.5˙ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.4˙ 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
0 0 0 0 0.7˙ 0 0 0 0 0.2˙ 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.7˙ 0.2˙ 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0.4˙ 0 0 0 0 0 0 0 0 0 0 0 0 0.5˙
Step 1: Counting Sites
As explained before, sites are the instances of a SLiM. In this step, we count the
number of sites for each SLiM in every protein sequences. For example, Fig. 9 shows
three SLiMs found from a set of proteins, and Fig. 10 is a protein sequence named
Q13838. According to three known SLiMs, we can point out all the sites for each
SLiM, which is the number of this motif. As shown in Fig. 9, we find out all the sites
of motif 7, and mark them in red. In the same way, Patterns in purple are sites of
motif 8, while green short chains are sites of motif 10. In this case, the score of motif
7 for protein Q13838 is set as 3, motif 8 is set as 2, and the number of motif 10 is 3.
Assume that there are 10 SLiMs extracted, a matrix like Table 6 can be generated.
Each row means a protein, while every column represents a SLiM.
Step 2: Scoring Sites using I-Formula
Rueda et al. [28] proposed I-formula in order to calculate I-score as the attributes of
predict obligate and non-obligate protein interaction complexes, and get a satisfying
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Fig. 9: (a) Motif 7, (b) Motif 8, (c) Motif 9
Fig. 10: Example of counting sites
result where the accuracy is more than 99%. Assume that given a protein sequence
X of length L and a SLiM m of length l with n sites, the I-score of SLiM m for
protein X is calculated according to Equation (1). In this formula, ai means the i
th
site of SLiM m, while aij is the j
th amino acid in site ai. In this case, P (aij) is the
probability of amino acid aij occurring on the j
th position of site ai, which can be
obtained from PSPM. Different length of SLiMs will affect the value, which may lead
Table 6: Counting sites matrix
SLiM 1 ... SLiM 7 SLiM 8 SLiM9 SLiM10
Q13838 0 0 3 2 0 3
...
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to an unfair comparison. It means that a higher value may be caused by a larger
size of SLiM since it is calculated by sum of values about probabilities of amino acids
in each site. The more amino acids contained in a site, the larger score it may be.
However, every SLiM is an equal attribute without any priority. To make it fair, it
should be divided by l which is the length of a SLiM.
I(m|X) = −1
l
×
l∑
j=1
P (aij)× log(P (aij)) (1)
Since 0 6 P (aij) 6 1, log(P (aij)) is negative, the higher probability a SLiM is, the
lower score we will get. To make it more meaningful, a negative sign is used in front
of the equation. Besides, log(P (aij)) = 0 when P (aij) = 1, which is meaningless. To
solve this problem, a regulation of P (aij) threshold is defined as follow:
log(P (aij)) =

log(1− ε) ifP (aij) > 1− ε
log(P (aij)) otherwise
(2)
where ε > 0, and ε is a sufficiently small value, and set as 0.01 in our experiment.
Step 3: Averaging I-Score
The final score of a SLiM should also be divided by the number of its sites which is
obtained in Step 1. Therefore, I formula is modified as below:
Iˆ(m|X) = − 1
n
×
n∑
i=1
(
1
l
×
l∑
j=1
P (aij)× log(P (aij))) (3)
Thus, every SLiM for each protein sequence will get an I-score.
3.2.3 Sliding Window Score Approach
This method is proposed by [22], and found a new way to define sites rather than
using the SLiMs extracted by MEME. Assume that given a protein sequence X of
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length L, and the length of a potential site s is l. Suppose that there is a window
which can show l amino acids, and place the window from the beginning of the protein
sequence. The pattern shown in this window consisting of the first l amino acids is
regarded as a potential site. It can be scored by the formula (4), where P (si) means
the probability of ith amino acid in site s occurring in the ith position of a SLiM.
The value of P (si) can be obtained from PSPM in MEME output file. Then move
the window to the next position, and score the pattern selected by the window in
the same way. Repeat the same operation until the window slides to the end of the
protein sequence X.
P (s|X) = 1
l
×
l∑
i=1
P (si) (4)
Next, we define a threshold λ. If P (s|X) is larger than λ, site s is considered as a
real site, and marked as a, otherwise, it is not a site. In this thesis, we set value of λ
as 0.4, 0.45, 0.5 and 0.6 to see which performance is better. Fig. 11 shows that given
a pattern of SLiM and its PSPM, how to find real sites using this method. Letters in
red represent the pattern shown in the window.
The purpose of this method is to calculate the value of SLiMs for every protein,
so after the score of each real site gotten, we need to add them together and divide
it by the number of real sites to get an average. Suppose that there are n real sites
of SLiM m in protein X, and ai means the i
th real site. According to Equation (5),
we can get the score of SLiM m.
P (m|X) = 1
n
×
n∑
i=1
P (ai|X) (5)
3.3 Drug Feature Representation
In this thesis, we use chemical substructure fingerprints [32][31][41] as drug feature
descriptors. PubChem database defines 881 fingerprints, while Klekota and Roth [21]
defines 4860 bits. Fig. 12 is a portion of fingerprints in PubChem, where the first
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Fig. 11: An example to show how to find real sites in sliding window score method
(λ = 0.6)
column is position number starting from 0 and end with 880, and the second column
is chemical structure. Klekota and Roth defines molecular fingerprints in a similar
way, but more particularly. In the following part, we focus on PubChem to explain
the principle, and Klekota and Roth is the same.
It is obvious that drug chemical formulas need to be gained first if we want to
identify descriptors of drugs. Simplified molecular-input line-entry system (SMILES)
is the chemical formula expression we used in this thesis. SMILES format can be
searched on KEGG public database according to the drug codes in the dataset. Fig.
13 shows this process.
According to 881 drug fingerprints defined by PubChem, each drug can be encoded
with 881 binary bits. If the substructure can be found in this compound, then set the
value of this fingerprint as 1, otherwise, set it as 0. Many tools have been developed
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Fig. 12: The first 25 chemical substructure fingerprints in PubChem
to find molecular fingerprints in drugs. rcdk package in R software is one of them.
This package is a JAVA framework for chemoinformatics, and can be imported into
R as the interface to CDK Libraries. It is developed to assess different kinds of
chemical compound descriptors. It can output the corresponding position numbers
whose substructures can be found in this drug based on SMILES format input. Fig.
14 is the R command and its output. We assign the SMILES expression to variable
smiles, and set the type of database as ′pubchem′. In this case, R prints the positions
Fig. 13: An example of SMILES format searching process
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whose fingerprints are satisfied.
Fig. 14: Command in R and its output to identify drug descriptors
According to the output, we can create a matrix like Table 7, where each column
represents a substructure position number, so there are 881 columns regarding Pub-
Chem. As we can see, the fingerprints on position 10, 11, 12, 13, 19 and 20 can be
found in this drug, then set the value on these positions as 1.
Table 7: Drug Feature Matrix
0 ... 10 11 12 13 14 15 ... 19 20 21 ... 880
Drug1 0 1 1 1 1 0 0 1 1 0 0
...
3.4 Negative Samples Selection
As mentioned before, reliable negative samples selection is a significant problem need
to be solved before classification. Based on two strategies proposed by [33] and
considering the specific problem in this thesis, we introduce a solution as follows.
Since interaction pairs between drugs and their target proteins are known, the
pairs which not shown as interacted are considered as unknown samples. For each
drug, we have known the features of its target proteins, and based on these fea-
tures, the most different proteins can be fingered out as the non-interacted proteins
in terms of this drug. To make it clear, suppose that there are m drugs and n
28
3. MATERIAL AND METHODOLOGY
proteins in a dataset, and marked as drug D = {d1, d2, d3, ..., dm}, target proteins
T = {t1, t2, t3, ..., tn}. If d1 interacts with t1, t2 and t3, which belongs to set PT
(positive target), then t4, t5, ... , tn are regarded as unknown state for d1, and such
set is named as UT (unknown targets). The next step is to find out the proteins
which have the largest differences between d1. Assume that there are k SLiMs as
attributes for each protein, the protein properties X = {x1, x2, x3, ..., xk} where each
element represents one attribute and consist of values for each protein of this feature.
It means that xi = {xi1, xi2, xi3, ...xin} where xin means the value of the ith feature
for the nth protein.
To define the weight for each attribute can follow Equation (6).
Wi =
mean(xi)
2/var(xi)∑k
j=1(mean(xj)
2/var(xj))
(6)
where mean(xi) is the average of xi:
mean(xi) =
1
n
×
n∑
j=1
xij (7)
and var(xi) is its variance:
var(xi) =
n∑
j=1
(xij −mean(xi))2 (8)
Then the deviation of ith protein ti is calculate as follows.
ξ(ti) =
k∑
j=1
(Wj ×
∣∣∣∣xji −mean(xj)mean(xj)
∣∣∣∣) (9)
The higher ξ(ti) is, the more deviation protein ti has, and the further away from
mean value. However, it can not illustrate that the most different point is in this
position. Moreover, it should be compared with positive data according to Equation
(10), where UT is a set storing unknown targets, while PT is a set of positive targets
which means the proteins interacted with this drug.
29
3. MATERIAL AND METHODOLOGY
P (ti ∈ UT ) =
∣∣∣∣∣ξ(ti)−mean(∑
j∈PT
ξ(tj))
∣∣∣∣∣ (10)
After that, we sort the proteins based on the value of P (ti) from high to low,
and selection preference is from high to low. To make it much fairer, we choose the
same number of non-interacted proteins as target ones for every drug to maintain the
same degree in positive and negative data. Next, the same operation can be done
for each drug to find out the most likely non-interacted proteins for this drug, and
vice versa. In terms of every protein, its targeted drugs can also be extracted, and
using the same formulas based on the features of drugs. In the same way, the most
different ones compared to the attributes of interacted drugs will be chosen, and the
same amount of drugs can still be selected as interacted ones for this protein. For
the rest of proteins, the same operations are repeated. After another negative set
obtained, we combine all the negative pairs fingered out during these two screenings
together. In this case, the number of negative data is twice larger than positive ones,
which may cause bias. To avoid this situation, we randomly select the same number
as positive ones from the combined set to be negative samples, and combine positive
and negative pairs together as the dataset need to be used for classification.
3.5 Classification and Validation
We have tried several classifiers in this research, such as k Nearest Neighbours (k-NN),
Random Forest (RF), and Support Vector Machine (SVM). Waikato Environment for
Knowledge Analysis (Weka) is the tool used to do the classification and validation in
this research. It integrates many classifiers including k-NN, RF and SVM, and also
outputs results of evaluation.
3.5.1 k-NN
k Nearest Neighbours (k-NN) is one of the most fundamental and simple classification
methods [27]. Assume that there are two classes, positive and negative. Given a test
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sample, find out its k nearest known-label neighbours. If there are more samples
belong to positive class among this k nearest neighbours, then regard this test sample
as positive; Otherwise, predict it as negative. In this thesis, we use 1-NN method,
which means that a test sample is predicted as the same class as its nearest training
sample.
There is a general formula for distance calculation called Minkowski distance which
is defined as Equation(11). d means dimension, which is the number of features.
d(x, y) = p
√√√√ d∑
i=1
|xi − yi|p (11)
When p = 1, Equation(11) is converted into Equation(12) which is called Manhattan
distance.
d(x, y) =
d∑
i=1
|xi − yi| (12)
When p = 2, Euclidean distance can be obtained as Equation (13). In this thesis, we
use Euclidean distance to find the nearest neighbours for each sample.
d(x, y) =
√√√√ d∑
i=1
(xi − yi)2 (13)
3.5.2 Random Forest
Generally speaking, Random Forest (RF) combines the definition of bagging and
decision tree together. It has an advantage in accuracy improvement, and does not
need to reduce the dimensionality. As the name implies, ‘forest’ means many decision
trees need to be built. Every time before building a decision tree, the training set is
constructed by randomly sampling from the original dataset with replacement, until
N samples chosen if N samples are needed. Samples unselected are regarded as a test
set. Such sampling method is named as bootstrap sample. Decision tree may cause
overfitting for the training set. To solve this problem, if there are M features totally,
when a decision needs to be done, we can randomly choose m features of them where
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m << M . Then choose one best feature from these m features to make a decision.
We can use the same method to build many decision trees as predictors, and branches
of these trees will not be pruned. Given a test sample, if it is classified as positive
class by more decision trees, this sample is predicted as positive class. Otherwise, it
is regarded as negative. This is like a voting system which depends on majority votes.
3.5.3 Support Vector Machine
Support vector machine (SVM) is a supervised learning method. The aim of SVM is
to separate the training data by a hyperplane with the largest margin. It uses the
concept of kernel instead of mapping data into a higher dimensional space. There are
mainly three types of kernel, which are linear, polynomial, and radial basis function
(RBF). In this thesis, we use RBF as the kernel of SVM. There are two parameters
which affect the performance of this classifier, γ and c. γ is the parameter of RBF
kernel, which controls the shape of separating function. To make it simple, it defines
how far the influence of a single training example reaches. c means cost, which is a
parameter for the soft margin cost function, and it indicates the level of punishment.
A lower c value allows higher error on the training set by finding larger margin, while
a higher c value will select few points within soft margin, and may cause overfitting.
We can improve the performance by modifying the values of parameter γ and c.
3.5.4 mRMR Feature Selection
mRMR is short for minimum-redundancy maximum-relevancy, which is a feature
selection method proposed by [26]. The purpose of feature selection is to choose
a subset of relevant features instead of using all the features to build a model for
classification. Feature selection is not the way to improve the performance, but to
make model more efficient. It will take less time, avoid curse of dimensionality, and
make the model simpler and more general. mRMR feature selection method considers
both high relevant between features and class and less redundancy among features.
Suppose that S represents feature subset, c is class label, f means feature, and
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I(a, b) is the information between a and b. Relevancy can be computed as Equation
(14).
D(S, c) =
1
|S|
∑
FiS
I(fi; c) (14)
Redundancy is calculated as follows.
R(S) =
1
|S|2
∑
fi,fj∈S
I(fi; fj) (15)
We can maximize Φ in oder to make relevancy maximum and redundancy mini-
mum.
Φ(D,R) = D −R (16)
3.5.5 Performance Evaluation
In order to validate the performance of different classifiers, we compare predicted
results with known classes. Cross-validation is a commonly used evaluation method.
The original dataset can be divided into two sets, training set and testing set. Training
set is used to build a model, while testing set is regarded as an unknown-label set to
do the prediction using this model. Since the labels of two classes have been known,
the results can be evaluated by some statistics measures, such as specificity, sensitivity
and accuracy, which are defined as Equation (17)(18)(19).
In this thesis, 10-fold cross validation is used as the evaluation method. First,
randomly divide the whole dataset into ten equal parts. Then select the first part as
a test set, while the rest nine sets are combined as a training set which is used to
build a model. After using this model to predict the test set, values of those measures
can be computed. Next, select the second part as a test set, while other nine parts
as a training set, and do the same operation to get another set of measured values.
Repeat the same work until every part are selected as a test set, and other nine sets
are used to build a model to do the prediction by the same classifier of the same
parameters. In this case, ten sets of measured values are obtained, and we can get
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an average for each as the final score for specificity, sensitivity and accuracy of this
classifier.
specificity =
TN
TN + FP
(17)
sensitivity =
TP
TP + FN
(18)
accuracy =
TP + TN
TP + TN + FP + FN
(19)
Assume that there are two classes, positive and negative. TP is the number of
True Positive samples, and True Positive means the samples are labeled as positive
(interaction) and also predicted as positive data. FP is the number of False Positive,
and False Positive means the samples are predicted as positive samples, but labeled
as negative in the original dataset, so this kind of samples are not real positive sam-
ples, and called as False Positive. In the same way, TN means the number of True
Negative samples, which are predicted as negative and indeed negative in fact. FN
is the number of False Negative data, which are positive ones indeed, but classified as
negative. Specificity is a measure that validates true negative rate, while sensitivity
is to evaluate true positive rate, and accuracy is an overall assessment considering
both positive and negative prediction.
AUC is another important measure which means the area under ROC curve. The
x-axis of ROC curve is False Positive rate, while y-axis is True Positive rate. The best
situation is that all the predicted positive samples are true, in this case, the value of
AUC is 1.
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CHAPTER 4
Results and Discussion
4.1 Results
In this chapter, we list all the results of four gold standard datasets generated using
different databases, methods, parameters, and classifiers. In terms of drug features,
we have tried two databases: PubChem and Klekota and Roth, consisting 881 and
4860 fingerprints respectively. For scoring SLiMs, we use two methods: I-score and
sliding window score (SWS) method, and the value of SWS threshold λ is set as 0.4,
0.45, 0.5 and 0.6 separately. Besides, three classifiers are used to do the prediction
Random Forest (RF), k-Nearest Neighbours (k-NN), and Support Vector Machine
(SVM). We set k as 1 concerning k-NN. Additionally, after trying different values of
parameter γ and c, we find that when γ = 0.01, c = 100, the performances of four
datasets are relatively better. Thus, we set γ as 0.01 and c as 100 for SVM in this
thesis. Moreover, there are four statistics measures used in this chapter, which are
AUC, accuracy, sensitivity and specificity.
Table 8 shows the results of Nuclear Receptor dataset using k-NN, RF and SVM
classifiers. Multi-rows of ‘881 fingerprints’ represent the results using 881 chemical
substructure fingerprints defined by PubChem database, while rows of ‘4860 finger-
prints’ are the measured values generated using 4860 fingerprints by Klekota and
Roth database. The row of ‘I-score’ shows the performance using I-score method
scoring SLiMs, while ‘SWS’ is short for sliding window score approach. Multi-rows of
SWS method are the results of different thresholds. As we can see from Table 8, the
performance of k-NN is relatively worse than RF and SVM in general. The value of λ
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effect the results in a certain degree, but not too much. Concerning Nuclear Receptor
dataset, The best AUC value is 0.8764 when regard 4680 fingerprints as drug features
and use SWS method with λ equals to 0.6 scoring SLiMs by RF, and its accuracy is
also the highest.
Table 9 shows the results of GPCR dataset, and the performance is much better
than Nuclear Receptor. The values of AUC are mostly higher than 0.9, while in terms
of RF, AUC values are all more than 0.96. It is evident that the performance of k-
NN is satisfied, but still not as excellent as RF and SVM. Additionally, the results
generated using 881 fingerprints are a little bit better than using 4860 fingerprints
for all classifiers. Moreover, it is interesting to note, the result of I-score performs
the best compared with SWS for k-NN, while this method has the worst performance
in SVM. In terms of AUC, RF is better than SVM, and the highest value occurs
when using PubChem database and SWS method with λ equals to 0.5, which AUC
is 0.9756. However, considering accuracy, SVM has higher scores, and the best value
is 0.938 with sensitivity is 0.928 sensitivity and 0.948 specificity.
As we can see from Table 10, the performance is satisfied in general. The values
of AUC for all conditions are mostly more than 0.9. Additionally, the results of
RF and SVM is still better than k-NN. Although AUC of RF is higher than SVM,
the accuracy of SVM is better. When λ = 0.45 in SWS, the accuracy reaches the
highest for both 881 and 4860 fingerprints, which are 0.929 and 0.934 separately. The
difference between these two types of fingerprints is not much in Ion Channel dataset.
The performance of Enzyme is shown as Table 11. Generally, AUC by k-NN is
around 0.95, while the accuracy is mostly higher than 0.94. In terms of RF, the
accuracy is more than 0.97, and AUC is up to 0.99. For SVM, the values of accuracy
are the same as AUC, which are mostly around 0.97.
4.2 Comparison
To compare the results intuitively for each dataset, we draw a series of bar charts
shown as Fig.15, and accuracy is used as the measure. Each bar graph compares
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Table 8: Results of Nuclear Receptor dataset
AUC Accuracy Sensitivity Specificity
k-NN
881
Fingerprints
I-score 0.7259 0.722 0.733 0.711
SWS
λ = 0.4 0.6718 0.644 0.733 0.556
λ = 0.45 0.7231 0.661 0.744 0.578
λ = 0.5 0.7118 0.683 0.700 0.667
λ = 0.6 0.7248 0.711 0.700 0.722
4860
Fingerprints
I-socre 0.7078 0.678 0.722 0.633
SWS
λ = 0.4 0.695 0.633 0.667 0.600
λ = 0.45 0.7331 0.678 0.633 0.722
λ = 0.5 0.7353 0.667 0.600 0.733
λ = 0.6 0.7096 0.639 0.500 0.778
RF
881
Fingerprints
I-score 0.8319 0.767 0.789 0.744
SWS
λ = 0.4 0.8459 0.789 0.833 0.744
λ = 0.45 0.8276 0.789 0.833 0.744
λ = 0.5 0.8426 0.800 0.789 0.811
λ = 0.6 0.8764 0.800 0.789 0.811
4860
Fingerprints
I-socre 0.8119 0.739 0.733 0.744
SWS
λ = 0.4 0.8141 0.750 0.789 0.711
λ = 0.45 0.7729 0.717 0.767 0.667
λ = 0.5 0.7910 0.744 0.744 0.744
λ = 0.6 0.7516 0.711 0.689 0.733
SVM
881
Fingerprints
I-score 0.7278 0.728 0.722 0.733
SWS
λ = 0.4 0.7000 0.700 0.756 0.644
λ = 0.45 0.7500 0.750 0.767 0.733
λ = 0.5 0.7500 0.750 0.744 0.756
λ = 0.6 0.7778 0.778 0.811 0.744
4860
Fingerprints
I-socre 0.7889 0.789 0.744 0.833
SWS
λ = 0.4 0.7056 0.706 0.733 0.678
λ = 0.45 0.7389 0.739 0.767 0.711
λ = 0.5 0.7333 0.733 0.733 0.733
λ = 0.6 0.7222 0.722 0.756 0.689
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Table 9: Results of GPCR dataset
AUC Accuracy Sensitivity Specificity
k-NN
881
Fingerprints
I-score 0.9159 0.916 0.934 0.898
SWS
λ = 0.4 0.9177 0.917 0.934 0.901
λ = 0.45 0.9217 0.921 0.928 0.915
λ = 0.5 0.9183 0.918 0.920 0.917
λ = 0.6 0.9191 0.916 0.915 0.917
4860
Fingerprints
I-socre 0.8874 0.887 0.902 0.871
SWS
λ = 0.4 0.9048 0.903 0.918 0.888
λ = 0.45 0.9199 0.919 0.918 0.920
λ = 0.5 0.8906 0.890 0.896 0.883
λ = 0.6 0.9004 0.894 0.891 0.896
RF
881
Fingerprints
I-score 0.9699 0.919 0.937 0.901
SWS
λ = 0.4 0.9703 0.920 0.946 0.893
λ = 0.45 0.9739 0.928 0.939 0.917
λ = 0.5 0.9756 0.934 0.942 0.926
λ = 0.6 0.9733 0.942 0.942 0.942
4860
Fingerprints
I-socre 0.9614 0.915 0.923 0.907
SWS
λ = 0.4 0.9664 0.922 0.928 0.917
λ = 0.45 0.9689 0.920 0.928 0.912
λ = 0.5 0.9634 0.921 0.926 0.917
λ = 0.6 0.9612 0.924 0.918 0.929
SVM
881
Fingerprints
I-score 0.9205 0.920 0.920 0.921
SWS
λ = 0.4 0.9236 0.924 0.926 0.921
λ = 0.45 0.9370 0.937 0.942 0.932
λ = 0.5 0.9354 0.935 0.931 0.940
λ = 0.6 0.9378 0.938 0.928 0.948
4860
Fingerprints
I-socre 0.9118 0.912 0.902 0.921
SWS
λ = 0.4 0.9181 0.918 0.918 0.918
λ = 0.45 0.9213 0.921 0.913 0.929
λ = 0.5 0.9244 0.924 0.922 0.924
λ = 0.6 0.9134 0.913 0.902 0.924
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Table 10: Results of Ion Channel dataset
AUC Accuracy Sensitivity Specificity
k-NN
881
Fingerprints
I-score 0.9209 0.897 0.883 0.911
SWS
λ = 0.4 0.8940 0.893 0.888 0.898
λ = 0.45 0.9042 0.899 0.896 0.903
λ = 0.5 0.9146 0.899 0.887 0.911
λ = 0.6 0.9185 0.902 0.909 0.894
4860
Fingerprints
I-socre 0.9232 0.897 0.884 0.909
SWS
λ = 0.4 0.8904 0.887 0.892 0.881
λ = 0.45 0.9069 0.901 0.896 0.907
λ = 0.5 0.9205 0.904 0.888 0.921
λ = 0.6 0.9175 0.903 0.910 0.896
RF
881
Fingerprints
I-score 0.9523 0.888 0.872 0.904
SWS
λ = 0.4 0.9475 0.874 0.888 0.860
λ = 0.45 0.9572 0.892 0.881 0.902
λ = 0.5 0.9542 0.888 0.874 0.901
λ = 0.6 0.9639 0.907 0.899 0.915
4860
Fingerprints
I-socre 0.9586 0.900 0.871 0.928
SWS
λ = 0.4 0.9417 0.865 0.844 0.886
λ = 0.45 0.9588 0.898 0.875 0.921
λ = 0.5 0.9573 0.899 0.877 0.921
λ = 0.6 0.9623 0.913 0.904 0.921
SVM
881
Fingerprints
I-score 0.8852 0.885 0.910 0.860
SWS
λ = 0.4 0.9194 0.919 0.928 0.911
λ = 0.45 0.9289 0.929 0.931 0.927
λ = 0.5 0.9119 0.912 0.915 0.909
λ = 0.6 0.9160 0.916 0.911 0.921
4860
Fingerprints
I-socre 0.8916 0.892 0.904 0.879
SWS
λ = 0.4 0.9123 0.912 0.913 0.911
λ = 0.45 0.9339 0.934 0.934 0.934
λ = 0.5 0.9272 0.927 0.917 0.938
λ = 0.6 0.9051 0.905 0.911 0.899
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Table 11: Results of Enzyme dataset
AUC Accuracy Sensitivity Specificity
k-NN
881
Fingerprints
I-score 0.9565 0.951 0.957 0.945
SWS
λ = 0.4 0.9519 0.947 0.957 0.937
λ = 0.45 0.9665 0.955 0.956 0.953
λ = 0.5 0.9656 0.954 0.956 0.953
λ = 0.6 0.9587 0.949 0.955 0.942
4860
Fingerprints
I-socre 0.9460 0.943 0.950 0.936
SWS
λ = 0.4 0.9355 0.933 0.954 0.912
λ = 0.45 0.9493 0.945 0.955 0.934
λ = 0.5 0.9571 0.949 0.958 0.941
λ = 0.6 0.9495 0.943 0.956 0.930
RF
881
Fingerprints
I-score 0.9914 0.977 0.974 0.980
SWS
=0.4 0.9913 0.972 0.965 0.979
λ = 0.45 0.9924 0.975 0.969 0.981
λ = 0.5 0.9901 0.975 0.967 0.982
λ = 0.6 0.9904 0.977 0.971 0.983
4860
Fingerprints
I-socre 0.9896 0.976 0.974 0.979
SWS
λ = 0.4 0.9885 0.976 0.977 0.975
λ = 0.45 0.9900 0.976 0.972 0.974
λ = 0.5 0.9904 0.977 0.975 0.978
λ = 0.6 0.9884 0.975 0.975 0.976
SVM
881
Fingerprints
I-score 0.9719 0.972 0.963 0.980
SWS
=0.4 0.9742 0.974 0.969 0.980
λ = 0.45 0.9764 0.976 0.969 0.984
λ = 0.5 0.9754 0.975 0.967 0.984
λ = 0.6 0.9772 0.977 0.967 0.987
4860
Fingerprints
I-socre 0.9687 0.969 0.973 0.965
SWS
λ = 0.4 0.9740 0.974 0.973 0.975
λ = 0.45 0.9719 0.972 0.972 0.972
λ = 0.5 0.9762 0.976 0.975 0.977
λ = 0.6 0.9750 0.975 0.974 0.976
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different scoring SLiMs methods, classifiers and various types of fingerprints. The
dark blue bars represent the accuracy using I-score method, yellow bars indicate the
accuracy when λ = 0.6 in SWS method, grey bars means λ = 0.5, bars in orange
are performances of λ = 0.45, and light blue ones are λ = 0.4. Generally speaking,
different scoring methods have little influence on the final results. The performance
of k-NN is quite satisfied, but relatively not as good as RF and SVM. Besides, the
results of 881 fingerprints are a little better than 4860 ones. In this case, if we focus
on the accuracy using 881 fingerprints, concerning RF, when the threshold is 0.6, the
accuracies are the best under most circumstances. For SVM, λ = 0.45 is the best
choice. However, the influence of different thresholds is not that much.
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Fig. 15: Comparison among different SLiMs scoring methods, classifiers and different
types of fingerprints for each dataset
We choose the performance by RF with 881 fingerprints as a condition comparing
the results among different datasets. The performance of I-score is moderate, so we
use I-score to do this comparison which is shown in Fig. 16. Obviously, the perfor-
mance of Nuclear Receptor is relatively not as satisfied as others. This may caused
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by less training samples. We believe that if enlarge the dataset, the performance will
be better. The performance of Enzyme proves this hypothesis.
0
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0.4
0.6
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1
1.2
AUC accuracy sensitivity specificity
RF	with	881	Fingerprints
Nuclear_receptor GPCR Ion_channel Enzyme
Fig. 16: Comparison among different datasets using RF with 881 fingerprints
Besides, we also want to compare the performance before mRMR feature selection
and after it. We choose AUC as the measure to evaluate the performance, and use
SVM with I-score and 881 fingerprints as the classifier. Table 12 shows the results
of SVM using mRMR, while Fig. 17 compares AUC of SVM using all the features
and feature subset selected by mRMR method. As we can see, AUC values become
lower after mRMR. This is a normal situation because features support classifiers to
do prediction. The results may be affected after reducing features. However, the aim
of feature selection is not to improve the accuracy, but make models simpler, so that
it may cost less time and avoid curse of dimensionality. Additionally, we can also find
out the most important features using mRMR.
After comparing the performance among different sets and different methods,
existing research comparison is also needed. We choose the AUC values generated
by RF with 881 fingerprints and SWS method with λ = 0.6 as the result of our
method. Table 13 lists the AUC values of some existing methods using the same
gold standard dataset, which are Cao et al (2012) [6], Bigram-PSSM [24], Yamanishi
et al. (2008) [39], Wang et al. (2010) [34], Yamanishi et al. (2010) [40], KBMF2K
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Table 12: Results of mRMR feature selection applied on SVM with I-score and 881
fingerprints
Nuclear Receptor GPCR Ion Channel Enzyme
AUC 0.7222 0.9024 0.8032 0.8832
Accuracy 0.722 0.902 0.803 0.883
Sensitivity 0.756 0.915 0.781 0.972
Specificity 0.689 0.890 0.825 0.794
0 0.2 0.4 0.6 0.8 1
Nuclear	Receptor
GPCR
Ion	Channel
Enzyme
With	mRMR Without	mRMR
Fig. 17: Comparison of AUC between with and without mRMR
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Table 13: The comparison of AUC among existing methods using benchmark datasets
Algorithms Enzyme Ion Channel GPCR Nuclear Receptor
Proposed Method 0.9904 0.9639 0.9733 0.8764
Cao et al. (2012) 0.9486 0.9428 0.8902 0.8822
Bigram-PSSM 0.948 0.889 0.872 0.869
Yamanishi et al. (2008) 0.904 0.851 0.899 0.835
Wang et al. (2010) 0.886 0.893 0.873 0.824
Yamanishi et al. (2010) 0.892 0.812 0.827 0.835
KBMF2K 0.832 0.799 0.857 0.824
NetCBP 0.8251 0.8034 0.8235 0.8394
DBSI 0.8075 0.8029 0.8022 0.7578
[15], NetCBP [7], and DBSI [9]. These existing methods are not only feature-based,
but using the same dataset to solve the same problem, so they are comparable. The
method proposed in this thesis outperforms the others regarding most datasets. In
terms of Nuclear Receptor dataset, the AUC value of our method is the second best,
which is also a satisfied result.
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Conclusion
We propose a new feature-based method to predict drug-target interaction which
firstly introduces short-linear motifs (SLiMs) as protein features into this field. Dif-
ferent from n-gram, SLiMs have biological meanings, so that they can represent pro-
tein features better. There are two approaches to score SLiMs: I-score and sliding
window score (SWS) which are calculated based on position-specific probability ma-
trix (PSPM), in order to generate protein feature matrix. Concerning drug features,
we select two kinds of chemical substructure fingerprints defined by PubChem and
Klekota and Roth databases, then generate a drug feature binary matrix as the rep-
resentation of drugs.
Another contribution of this research is to find a strategy to extract negative data
from unknown samples. This point is often ignored by many previous studies, but
necessary to be considered. We select negative samples by finding out drug-target
pairs with the largest difference from known interacted samples, and also considering
balanced degrees between positive and negative data to avoid bias.
After getting all the results, we find that the performance of RF and SVM is better
than k-NN, and using the fingerprints defined by PubChem is the best choice. The
influence of different values of threshold λ in SWS method is not much for the final
results. Additionally, when λ = 0.6, the accuracy of RF classifier is relatively higher
in most conditions. Besides, SVM with λ = 0.45 is also a good choice. Compared
with the other existing study using the same dataset, our results are the best under
most circumstance. It indicates that this method is efficient and reliable.
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